Breast cancer treatment and ovarian failure: Risk factors and emerging genetic determinants

Vered Stearns, Bryan Schneider, N. Lynn Henry, Daniel F. Hayes, David A. Flockhart

Research output: Contribution to journalReview article

62 Scopus citations

Abstract

Most premenopausal women diagnosed with primary breast cancer receive adjuvant chemotherapy, and many experience chemotherapy-induced ovarian failure (CIOF). CIOF is associated with menopausal symptoms, fertility concerns and long-term implications including bone loss. Ironically, CIOF might confer a disease-specific benefit to women whose breast cancers express hormone receptors. Risk factors of CIOF include the woman's age at the time of therapy, and the type, dose and schedule of chemotherapy. Because inherited genetic factors have an important role in determining who will experience CIOF, genetic testing has the potential to provide optimal counselling about risks and possible interventions.

Original languageEnglish (US)
Pages (from-to)886-893
Number of pages8
JournalNature Reviews Cancer
Volume6
Issue number11
DOIs
StatePublished - Nov 12 2006

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Breast cancer treatment and ovarian failure: Risk factors and emerging genetic determinants'. Together they form a unique fingerprint.

  • Cite this